The Real Problem Is Not Hospital Prices, It Is Price Theater

When a price exists only if you ask the right way

What does it mean when the same hospital gives you one price online and a different one over the phone, sometimes by 50 percent or more? The easy answer is that healthcare is messy. The more unsettling answer is that the price itself may be performing a role, not doing a job.

That is the deeper tension hiding inside healthcare pricing today. We keep treating prices as if they are simple numbers, when in reality they are often negotiating tools, compliance artifacts, and institutional signals. A hospital price can be a promise, a decoy, a benchmark, or a shield, depending on who is asking and why. Once you see that, the confusion around hospital bills stops looking like a collection of administrative glitches and starts looking like a system built around managed ambiguity.

That same ambiguity is not limited to hospitals. It runs through the broader machinery of American healthcare, including the obscure but powerful 340B drug program, whose roots trace back to drug rebate rules created in 1990. Like hospital price transparency, 340B lives inside a world where the stated purpose of a policy and the incentives it creates are not always the same thing. The result is a system where numbers are everywhere, but truth is scarce.

Prices are not just numbers, they are institutional behavior

In a normal market, a price does three things at once. It tells you what you will pay, it helps you compare options, and it disciplines sellers. If a store posts one price online and another at checkout, that is usually a bug or a scandal. In healthcare, that same split is often treated as a tolerable feature of complexity.

But complexity alone does not explain why estimates vary so dramatically between online tools and phone calls. If one hospital quotes a patient a childbirth price of $12,000 online and $18,000 over the phone, the issue is not only technical. It suggests that the pricing system has multiple audiences. The online estimate may be designed for compliance, the phone estimate for flexibility, and the actual bill for later negotiation. In that kind of environment, the price is less like a label on a box and more like a passport stamp, useful for crossing one bureaucratic border but not necessarily another.

This is why transparency rules often disappoint. They assume that if prices are visible, markets will become disciplined. But visibility is not the same as comparability, and comparability is not the same as accountability. A price posted in a machine-readable file can still be functionally useless if it is incomplete, inconsistent, or detached from the patient’s actual financial path.

A price that cannot be trusted is not a price in the economic sense. It is a signal, and signals can be manipulated.

That is the crucial distinction. In healthcare, the question is not only, “What does this cost?” It is also, “Who is this number for, and what behavior is it trying to produce?”

The hidden economy of ambiguity

The phone versus online discrepancy is revealing because it exposes the hidden economy inside hospitals. Hospitals are not just care delivery organizations. They are also reimbursement negotiators, compliance responders, charity care administrators, and risk managers. Each role creates a different reason to present a different number.

Think of it like a restaurant that offers four separate menus: one for tourists, one for locals, one for corporate clients, and one for inspectors. Every menu is real. None of them fully describes what dinner will cost. That is how pricing can function in healthcare when the institution is trying to satisfy regulators, insurers, and patients at once.

This is where transparency efforts often run into a structural problem. They are built on the assumption that opacity is accidental. In many cases, it is strategic. That does not mean every hospital is acting in bad faith. It means that when margins are tight, payments are negotiated, and rules are unevenly enforced, ambiguity becomes a survival strategy.

The study of price discrepancies matters because it shows that the system can produce different answers to the same question depending on how the question is asked. That is more than a data-quality issue. It is a sign that price discovery, the process by which markets normally coordinate around value, has been fragmented into separate channels that do not fully talk to each other.

The practical effect is profound. Patients are asked to behave like consumers in a market that does not reliably supply consumer-grade information. They are told to compare prices, yet the prices themselves shift with context, method, and institutional posture. This is not a functioning marketplace. It is a price theater.

Why 340B belongs in the same conversation

At first glance, a hospital price discrepancy study and a discussion of the 340B drug program seem like separate issues. One is about patient-facing estimates. The other is about drug purchasing rules. But they are actually variants of the same deeper problem: when policy creates value through complexity, institutions learn to exploit complexity.

The 340B program emerged from drug rebate policy in the early 1990s, with an original aim tied to helping eligible hospitals and clinics stretch scarce resources. Over time, it became one of the most contested programs in healthcare because its rules, incentives, and downstream effects are hard to see from the outside. That is the key connection. Just as hospital pricing can split into different estimates depending on the channel, 340B can split into different interpretations depending on who is describing it: safety net support, a cross-subsidy, a revenue engine, a patient benefit, or a policy loophole.

Programs like 340B thrive in the same environment that allows pricing discrepancies to persist: a world where the formal rule is simple enough to pass legislation, but the operational reality is complex enough to generate multiple local strategies. Once that happens, institutions stop asking, “What is the clearest version of the number?” and start asking, “What number helps us comply, survive, and maximize flexibility?”

This is not corruption in the cartoon sense. It is something more ordinary and more durable: incentive-driven interpretation. When a rule creates money, hospitals and affiliated entities naturally learn to interpret it in ways that preserve access to that money. When a price is supposed to be transparent but the system rewards opacity, the price becomes part of the institution’s defensive language.

That is why 340B is relevant here. It reminds us that healthcare policy does not merely regulate behavior. It also teaches organizations how to narrate their own behavior. The institutions that master the narrative often master the economics.

The deeper question: are we measuring care or managing legitimacy?

The most important insight from putting these ideas together is that healthcare pricing may be doing a dual job. On paper, it is supposed to measure the cost of care. In practice, it often manages legitimacy.

Legitimacy management looks like this: a hospital publishes a price file because it must. It provides a phone estimate because a patient asks. It negotiates a payer rate because insurers require it. It justifies 340B participation because the hospital says it serves vulnerable communities. Each claim may be partially true. The system as a whole, however, is designed less around delivering a single coherent truth and more around defending the institution against the different audiences that can challenge it.

That helps explain why transparency efforts can feel so disappointing. We keep expecting a clean reveal, as if the problem is that the curtain is closed. But the curtain is not the whole problem. The stage itself is crowded with conflicting incentives. A hospital may reveal one number while still preserving enough ambiguity to preserve negotiating leverage, protect margins, or buffer uncertainty.

This is why simplistic slogans like “just post the price” do not go far enough. Posting is not the end of transparency. It is the beginning of a new contest over interpretation. If the number is incomplete, if the estimate excludes common services, if the quote changes depending on whether someone is calling from a cash-pay line or a billing department, then visibility merely shifts the battlefield.

A better model is to think in layers:

1. Posted price: the number that fulfills the formal requirement.
2. Quoted price: the number given when a patient or caller asks.
3. Negotiated price: the number that actually survives institutional bargaining.
4. Real price: the amount that matters after claims processing, discounts, subsidies, and follow-up billing.

Most public debate focuses on layer 1 and assumes that layer 4 will follow automatically. It rarely does.

What real reform would target

If the problem is price theater, then the solution is not merely more numbers. It is better alignment between numbers and consequences.

That means transparency rules need teeth, but also context. A hospital should not just be required to publish a price. It should be required to publish a price that is consistent across channels, clearly defined, and tied to standardized service bundles. For example, a vaginal childbirth estimate should specify what is included, what could change it, and how often it has matched actual bills over the past year. A brain MRI quote should clarify whether anesthesia, contrast, facility fees, and physician reading fees are included.

It also means policymakers need to ask a harder question about programs like 340B: who benefits, how measurable is the benefit, and what stops the benefit from becoming a revenue stream detached from patient care? Every policy that creates hidden value will eventually produce strategic behavior. The goal is not to eliminate strategy, which is impossible, but to constrain the distance between the policy’s stated purpose and its operating reality.

That distance is where trust goes to die. Patients do not need healthcare institutions to be perfect. They need them to be legible. A system can tolerate high prices more easily than it can tolerate arbitrary prices. It can even tolerate complexity if the rules are stable. What it cannot tolerate, over time, is the sense that every answer depends on the channel, every channel depends on the ask, and every ask depends on how much leverage the institution has that day.

Key Takeaways

• Do not confuse transparency with clarity. A posted number is only useful if it is standardized, complete, and consistent across channels.
• Treat inconsistent prices as a signal, not a glitch. Large discrepancies often reveal incentive misalignment inside the organization.
• Ask what role the price is playing. Is it meant to comply, negotiate, deter, or inform? Different roles produce different numbers.
• Look beyond the sticker price. In healthcare, the real price may include fees, discounts, subsidies, and later billing adjustments.
• Evaluate policy by behavior, not intention. Programs like 340B should be judged by how they shape institutional incentives over time, not only by their original purpose.

The real lesson: healthcare is not missing prices, it is missing a price grammar

The most useful way to think about this is not as a failure of disclosure but as a failure of language. Healthcare has plenty of numbers. What it lacks is a shared grammar that tells us what those numbers mean, when they apply, and how much faith to place in them.

That is why the same hospital can tell two different stories about the same service, and why a major drug policy can persist for decades while remaining misunderstood by the public. The problem is not that the system has no words. It is that it uses too many overlapping dialects, each optimized for a different audience.

Once you understand that, the path forward becomes clearer. The goal is not merely to make healthcare cheaper, though that matters. The goal is to make it legible enough that price stops being theater and starts being information. Until then, patients will keep doing the impossible task the system hands them: making life-defining decisions from numbers that were never fully meant to mean what they say.